BACKGROUND: Heart rate (HR) reduction in patients with systolic heart failure (HF) is a cornerstone of current therapy. The aim of this study was to evaluate the short-term effect of the HR reduction with ivabradine on N-terminal pro-brain natriuretic peptide (NT-proBNP) in outpatients with systolic HF. HYPOTHESIS: Ivabradine improves survival and promotes left ventricle remodelling by reducing resting heart rate. Nt-ProBNP absolute and trends predict prognosis. We hypothesized a possible association between heart rate decrease and Nt-ProBNP values. METHODS: We included 25 outpatients with systolic HF on optimized medical therapy (80% on angiotensin-converting enzyme inhibitors, 56% on spironolactone, and 88% on β-blocker therapy), left ventricle ejection fraction <40%, and sinus rhythm and HR >70/bpm. After a 1 month running-out period, to establish the clinical and NT-proBNP stability, patients were started on ivabradine for 3 months. RESULTS: Ivabradine decreased NT-proBNP (P = 0.002) from a median of 2850 pg/mL to 1802 pg/mL, corresponding to a median absolute and percent decrease of 964 pg/mL and 44.5%, respectively. The baseline HR correlated significantly with the baseline NT-proBNP (rs = 0.411, P = 0.041). The absolute and percent HR decrease correlated with the absolute NT-proBNP decrease (rs = 0.442, P = 0.027; rs = 0.395, P = 0.05). The greater the NT-proBNP absolute decrease tertile, the greater the baseline HR (P = 0.023) and the absolute (P = 0.028) and percent (P = 0.064) HR variation. CONCLUSIONS: In outpatients with systolic HF, the NT-proBNP reduction obtained by short-term ivabradine treatment correlates closely with the degree of HR reduction.
BACKGROUND: Heart rate (HR) reduction in patients with systolic heart failure (HF) is a cornerstone of current therapy. The aim of this study was to evaluate the short-term effect of the HR reduction with ivabradine on N-terminal pro-brain natriuretic peptide (NT-proBNP) in outpatients with systolic HF. HYPOTHESIS: Ivabradine improves survival and promotes left ventricle remodelling by reducing resting heart rate. Nt-ProBNP absolute and trends predict prognosis. We hypothesized a possible association between heart rate decrease and Nt-ProBNP values. METHODS: We included 25 outpatients with systolic HF on optimized medical therapy (80% on angiotensin-converting enzyme inhibitors, 56% on spironolactone, and 88% on β-blocker therapy), left ventricle ejection fraction <40%, and sinus rhythm and HR >70/bpm. After a 1 month running-out period, to establish the clinical and NT-proBNP stability, patients were started on ivabradine for 3 months. RESULTS:Ivabradine decreased NT-proBNP (P = 0.002) from a median of 2850 pg/mL to 1802 pg/mL, corresponding to a median absolute and percent decrease of 964 pg/mL and 44.5%, respectively. The baseline HR correlated significantly with the baseline NT-proBNP (rs = 0.411, P = 0.041). The absolute and percent HR decrease correlated with the absolute NT-proBNP decrease (rs = 0.442, P = 0.027; rs = 0.395, P = 0.05). The greater the NT-proBNP absolute decrease tertile, the greater the baseline HR (P = 0.023) and the absolute (P = 0.028) and percent (P = 0.064) HR variation. CONCLUSIONS: In outpatients with systolic HF, the NT-proBNP reduction obtained by short-term ivabradine treatment correlates closely with the degree of HR reduction.
Authors: Morten Schou; Finn Gustafsson; Per H Nielsen; Lene H Madsen; Andreas Kjaer; Per R Hildebrandt Journal: Eur J Heart Fail Date: 2006-07-07 Impact factor: 15.534
Authors: Colin Berry; Niamh F Murphy; Niamh Murphy; Giuseppe De Vito; Stuart Galloway; Alison Seed; Carol Fisher; Naveed Sattar; Patrick Vallance; W Sewart Hillis; John McMurray Journal: Eur J Heart Fail Date: 2006-11-27 Impact factor: 15.534
Authors: Franz Hartmann; Milton Packer; Andrew J S Coats; Michael B Fowler; Henry Krum; Paul Mohacsi; Jean L Rouleau; Michal Tendera; Alain Castaigne; Stefan D Anker; Ildiko Amann-Zalan; Silke Hoersch; Hugo A Katus Journal: Circulation Date: 2004-09-20 Impact factor: 29.690
Authors: Alan Maisel; Christian Mueller; Kirkwood Adams; Stefan D Anker; Nadia Aspromonte; John G F Cleland; Alain Cohen-Solal; Ulf Dahlstrom; Anthony DeMaria; Salvatore Di Somma; Gerasimos S Filippatos; Gregg C Fonarow; Patrick Jourdain; Michel Komajda; Peter P Liu; Theresa McDonagh; Kenneth McDonald; Alexandre Mebazaa; Markku S Nieminen; W Frank Peacock; Marco Tubaro; Roberto Valle; Marc Vanderhyden; Clyde W Yancy; Faiez Zannad; Eugene Braunwald Journal: Eur J Heart Fail Date: 2008-08-29 Impact factor: 15.534
Authors: Paul Mulder; Stephane Barbier; Abdeslam Chagraoui; Vincent Richard; Jean Paul Henry; Françoise Lallemand; Sylvanie Renet; Guy Lerebours; Florence Mahlberg-Gaudin; Christian Thuillez Journal: Circulation Date: 2004-02-23 Impact factor: 29.690
Authors: Rebecca A Capel; Neil Herring; Manish Kalla; Arash Yavari; Gary R Mirams; Gillian Douglas; Gil Bub; Keith Channon; David J Paterson; Derek A Terrar; Rebecca-Ann B Burton Journal: Heart Rhythm Date: 2015-05-27 Impact factor: 6.343
Authors: Peter Jirak; Dzeneta Fejzic; Vera Paar; Bernhard Wernly; Rudin Pistulli; Ilonka Rohm; Christian Jung; Uta C Hoppe; P Christian Schulze; Michael Lichtenauer; Atilla Yilmaz; Daniel Kretzschmar Journal: Acta Pharmacol Sin Date: 2017-12-14 Impact factor: 6.150
Authors: Gaidaa M Dogheim; Ibtsam Khairat; Gamal A Omran; Sahar M El-Haggar; Ahmed M El Amrawy; Rehab H Werida Journal: Eur J Clin Pharmacol Date: 2022-03-03 Impact factor: 3.064